Clinical Trials Browser

OTHER × Pancreatic Ductal Adenocarcinoma × tislelizumab × Clear all

NCT05303090 2025-02-27

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Phase 1 Completed

Gastrointestinal

Pancreatic Ductal Adenocarcinoma